title: Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression.
abstract: BACKGROUND
  Major histocompatibility complex class I-related chain A and B (MICA/B) are two stress-inducible ligands that bind the immunoreceptor NKG2D and play an important role in mediating the cyotoxicity of NK and T cells. In this study, we sought to study MICA/B expression in pancreatic cancer and to determine whether and how genotoxic drugs such as gemcitabine can affect MICA/B expression and natural killer cytotoxity.
  
  
  METHODS
  Seven pancreatic cancer cell lines were analyzed for MICA/B expression by flow cytometry and for their sensitivity to NK-92 cell killing by a 51Cr release assay. MICA/B expression in tumor tissues and sera of pancreatic cancer was analyzed by immunohistochemical staining (IHC) and ELISA, respectively.
  
  
  RESULTS
  Two MICA/B-positive cell lines were sensitive to the cytotoxic activity of NK-92 cells. Other two MICA/B-positive cell lines and three MICA/B-negative cell lines were resistant to NK-92 cell killing. MICA/B expression was positive in 17 of 25 (68%) pancreatic ductal adenocarcinomas but not in normal pancreatic ductal epithelial cells. Serum MICA/B levels were significantly elevated in patients with pancreatic adenocarcinomas but did not correlate with the stage of pancreatic cancer and patient survival. Gemcitabine therapy led to increased serum MICA levels in 6 of 10 patients with detectable serum MICA. Allopurinol, an inhibitor of xanthine oxidoreductase that converts xanthine to uric acid, blocked uric acid production, MICA/B expression, and sensitivity to NK-92 cell killing toward a PANC-1 cancer cell line exposed to radiation and two genotoxic drugs, gemcitabine and 5-fluorouracil.
  
  
  CONCLUSIONS
  The levels of MICA/B expression in serum and tissue of pancreatic cancer are elevated. DNA damage-induced MICA/B expression is mediated through increased uric acid production.
authors: Department of General Surgery, Rush University Medical Center, Chicago, IL 60612, USA. xxu@rush.edu
authors: Xiulong
authors: X
authors: Xu
authors: Geetha S
authors: GS
authors: Rao
authors: Veronika
authors: V
authors: Groh
authors: Thomas
authors: T
authors: Spies
authors: Paolo
authors: P
authors: Gattuso
authors: Howard L
authors: HL
authors: Kaufman
authors: Janet
authors: J
authors: Plate
authors: Richard A
authors: RA
authors: Prinz
references: Clin Cancer Res. 2008 Mar 1;14(5):1455-63
references: 18316569
references: Cancer Res. 2009 Oct 15;69(20):8050-7
references: 19826051
references: J Immunol. 2003 Aug 15;171(4):1909-17
references: 12902493
references: J Clin Oncol. 2009 Dec 10;27(35):5911-8
references: 19805669
references: J Clin Invest. 2003 Apr;111(8):1116-8
references: 12697728
references: Cancer Res. 2004 Mar 15;64(6):2175-82
references: 15026360
references: Med Oncol. 2011 Jun;28(2):466-74
references: 20354827
references: J Immunother. 2008 Jun;31(5):475-86
references: 18463537
references: J Clin Endocrinol Metab. 2006 Jul;91(7):2704-12
references: 16621903
references: J Immunol. 2010 Apr 1;184(7):3346-50
references: 20208009
references: Adv Immunol. 2000;76:1-60
references: 11079097
references: J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41
references: 18713817
references: Clin Cancer Res. 2008 Jun 1;14(11):3520-8
references: 18519785
references: Science. 1998 Mar 13;279(5357):1737-40
references: 9497295
references: Nature. 2001 Sep 13;413(6852):165-71
references: 11557981
references: Nature. 2002 Oct 17;419(6908):734-8
references: 12384702
references: J Clin Invest. 2004 Aug;114(4):560-8
references: 15314693
references: Nat Rev Immunol. 2003 Oct;3(10):781-90
references: 14523385
references: J Hematother Stem Cell Res. 2001 Aug;10(4):535-44
references: 11522236
references: Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4510-5
references: 9539768
references: Nat Med. 2003 Mar;9(3):269-77
references: 12612576
references: Cancer Immunol Immunother. 2005 Sep;54(9):915-25
references: 15782312
references: Cancer Res. 2002 Nov 1;62(21):6178-86
references: 12414645
references: Exp Hematol. 2005 Mar;33(3):344-52
references: 15730858
references: Int J Cancer. 2002 Jul 1;100(1):63-70
references: 12115588
references: Nature. 2005 Aug 25;436(7054):1186-90
references: 15995699
references: J Immunol. 2002 Oct 15;169(8):4098-102
references: 12370336
references: Int J Cancer. 2003 Apr 10;104(3):354-61
references: 12569559
references: Int J Cancer. 2006 Nov 15;119(10):2359-65
references: 16929491
references: Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9452-7
references: 12878725
references: J Hematother Stem Cell Res. 2001 Jun;10(3):369-83
references: 11454312
references: J Immunol. 2002 May 1;168(9):4772-80
references: 11971028
references: N Engl J Med. 2010 Apr 29;362(17):1605-17
references: 20427809
references: Lancet. 2004 Mar 27;363(9414):1049-57
references: 15051286
references: Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6879-84
references: 10359807
references: Cancer Biol Ther. 2003 Jul-Aug;2(4):446-51
references: 14508119
references: J Immunol. 2002 Nov 15;169(10):5377-81
references: 12421908
references: Cancer Res. 2008 Aug 1;68(15):6368-76
references: 18676862
references: Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12445-50
references: 8901601